

***Continued Examination Under 37 CFR 1.114***

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 1/17/08 has been entered.

**EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Csaba Henter on 2/8/08.

The application has been amended as follows:

**IN THE CLAIMS:**

- In claim 1, the phrase -or alternatively- has been deleted from line 14 of the claim. The deleted phrase follows the following text: "CR<sup>1</sup>R<sup>2</sup> carbon to the alpha CR<sup>3</sup>R<sup>4</sup> carbon;"

Art Unit: 1621

- Claim 16 now reads: A method of activating the PPAR $\alpha$  and PPR $\gamma$  isoforms in regulation of lipidaemia and glycaemia comprising administering an effective amount of a pharmaceutical composition according to claim 14.
  
- Claim 38 now read: A method of activating the PPAR $\alpha$  and PPR $\gamma$  isoforms in regulation of lipidaemia and glycaemia comprising administering an effective amount of a pharmaceutical composition according to claim 37.

/Yvonne L. Eyler/

Supervisory Patent Examiner, Art Unit 1621